IPO Year: 2024
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $44.00 | Buy | Guggenheim |
| 10/8/2024 | $40.00 | Buy | Stifel |
| 10/8/2024 | $35.00 | Buy | Jefferies |
| 10/8/2024 | $30.00 | Overweight | JP Morgan |
Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today annou
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)
SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)
SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)
SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)
SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)
SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)
SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)
SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)
Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today annou
CARMEL, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, 2025, at 2:15 p.m. Pacific Time. The Company will also participate in 1-on-1 investor meetings during the conference. Live webcasts can be accessed on the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the
CARMEL, Ind., Dec. 02, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the publication of a peer-reviewed article highlighting results from the Phase 1 study of MBX 2109, the Company's parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism (HP). The publication, titled "MBX 2109, a Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-in-Human, Randomized Trial", was published in The Journal of Clinical Endocrinology and Met
CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject's last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company's long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist in development for the treatment of post-bariatric hypoglycemia (PBH). "We are pleased to complete the last subject visit in our Phase 1 trial of MBX 1416 in healthy adults and extend our sincere appreciation to the partici
Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last subject last visit in Phase 1 trial of MBX 1416 anticipated by late November; topline results to be reported in early January 2025 Enrollment of Phase 2 Avail™ trial of MBX 2109 in hypoparathyroidism on track to complete in Q1 2025; topline results anticipated in Q3 2025 Strong cash position, with $277.1 million expected to support operations into mid-2027 CARMEL, Ind., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies fo
CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its management team will participate in the following upcoming investor conferences: Guggenheim Inaugural Healthcare Innovation Conference Date: Tuesday, November 12, 2024Format: Fireside chatTime: 3:30 p.m. ESTLocation: Boston, MA Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024Format: Fireside chatTime: 3:00 p.m. ESTLocation: New York, NY Jefferies London Healthcare Conference Date: Wedne
CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX) ("MBX Biosciences"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the closing of its previously announced upsized initial public offering of 11,730,000 of its common stock at a price to the public of $16.00 per share, which includes 1,530,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The aggregate gross proceeds to MBX Biosciences from the offering were approximately
8-K - MBX Biosciences, Inc. (0001776111) (Filer)
10-Q - MBX Biosciences, Inc. (0001776111) (Filer)
8-K - MBX Biosciences, Inc. (0001776111) (Filer)
8-K - MBX Biosciences, Inc. (0001776111) (Filer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
4 - MBX Biosciences, Inc. (0001776111) (Issuer)
Guggenheim initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $44.00
Stifel initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $40.00
Jefferies initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $35.00
JP Morgan initiated coverage of MBX Biosciences with a rating of Overweight and set a new price target of $30.00